AAM Blasts Build Back Better But Bernstein Offers Balance

Discounted Drugs Could Disincentivize US Biosimilar Competition, Says AAM

 
• By Chloe Kent
  
Joe Biden stands in front of a Build Back Better poster
Build Back Better's proposed price controls could have a negative affect on the biosimilars industry • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Policy & Regulation

More from Generics Bulletin